Heterologous Epitope-Scaffold Prime∶Boosting Immuno-Focuses B Cell Responses to the HIV-1 gp41 2F5 Neutralization Determinant by Guenaga, Javier et al.
Heterologous Epitope-Scaffold Prime:Boosting Immuno-






3, William R. Schief
3, Peter D. Kwong
1,
Gunilla B. Karlsson Hedestam
2, Richard T. Wyatt
1*
¤
1Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, United States of America, 2Department of Microbiology, Tumor and Cell Biology, Karolinska
Institutet, Stockholm, Sweden, 3University of Washington, Seattle, Washington, United States of America
Abstract
The HIV-1 envelope glycoproteins (Env) gp120 and gp41 mediate entry and are the targets for neutralizing antibodies.
Within gp41, a continuous epitope defined by the broadly neutralizing antibody 2F5, is one of the few conserved sites
accessible to antibodies on the functional HIV Env spike. Recently, as an initial attempt at structure-guided design, we
transplanted the 2F5 epitope onto several non-HIV acceptor scaffold proteins that we termed epitope scaffolds (ES). As
immunogens, these ES proteins elicited antibodies with exquisite binding specificity matching that of the 2F5 antibody.
These novel 2F5 epitope scaffolds presented us with the opportunity to test heterologous prime:boost immunization
strategies to selectively boost antibody responses against the engrafted gp41 2F5 epitope. Such strategies might be
employed to target conserved but poorly immunogenic sites on the HIV-1 Env, and, more generally, other structurally
defined pathogen targets. Here, we assessed ES prime:boosting by measuring epitope specific serum antibody titers by
ELISA and B cell responses by ELISpot analysis using both free 2F5 peptide and an unrelated ES protein as probes. We found
that the heterologous ES prime:boosting immunization regimen elicits cross-reactive humoral responses to the structurally
constrained 2F5 epitope target, and that incorporating a promiscuous T cell helper epitope in the immunogens resulted in
higher antibody titers against the 2F5 graft, but did not result in virus neutralization. Interestingly, two epitope scaffolds
(ES1 and ES2), which did not elicit a detectable 2F5 epitope-specific response on their own, boosted such responses when
primed with the ES5. Together, these results indicate that heterologous ES prime:boost immunization regimens effectively
focus the humoral immune response on the structurally defined and immunogen-conserved HIV-1 2F5 epitope.
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Introduction
Most effective anti-viral vaccines protect by the elicitation of
neutralizing antibodies [1,2], therefore the elicitation of broadly
neutralizing antibodies to the surface-exposed HIV-1 envelope
glycoprotein (Env) spike is likely a critical component for an
effective HIV-1 vaccine. The trimeric spike is comprised of the
highly N-glycosylated exterior Env, gp120, and the non-covalently
associated transmembrane Env, gp41 and is the sole virally
encoded target for neutralizing antibodies [3]. The gp120 subunit
binds the host primary cellular receptor, CD4, and following
receptor-induced conformational changes, the target cell co-
receptor, CCR5 [4,5,6]. Following CCR5 engagement by
gp120, gp41 mediates viral-to-target cell fusion, facilitating entry
of viral genetic information into the cell and onset of retroviral
infection.
During chronic HIV-1 infection, selected individuals generate
broadly neutralizing antibodies to the functional Env spike
[7,8,9,10,11,12,13,14,15,16], and a subset of these responses
map to conserved elements of Env [17,18]. However, in general,
the elicitation of broadly neutralizing HIV-1 antibodies following
natural infection appears relatively inefficient [19,20,21,22,23].
Reflective of this inefficiency, until recently, only four broadly
neutralizing antibodies isolated from HIV-1-infected individuals
were described. Two of these antibodies bind to conserved
epitopes in the gp120 subunit, b12 and 2G12 [24,25]; and two
bind to conserved, contiguous epitopes in the gp41 subunit, 2F5
and 4E10 [26,27]. In the past year, several new broadly
neutralizing antibodies have been described and include the
trimer-preferring antibodies, PG9 and PG16, and the CD4
binding site antibodies HJ16, VRC01/2 and VRC03 [28,29,30].
The gp41-directed 2F5 and 4E10 antibodies target the gp41
membrane external proximal region (MPER), and are accessible at
some not yet well defined juncture during viral entry, permitting
MPER-directed neutralization [31,32]. Numerous prior efforts to
elicit antibodies against this gp41 region using diverse MPER-base
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that displayed limited, weak, or no neutralization activity [33,
34,35,36,37,38,39,40]. The peptide epitope conformations of the
MPER-directed neutralizing antibodies are crystallographically
defined in complex with the corresponding Fab fragment at the
atomic level of resolution, allowing structure-guided pathways for
immunogen design. A novel and recently described method for
immunogen design known as ‘‘scaffolding’’ uses the power of
computational design to engraft the 2F5 epitope in its unusual and
fixed conformation onto selected unrelated, non-HIV derived
protein ‘acceptor’ scaffolds [41], and similarly applied for the 4E10
epitope [42]. The 2F5 linear epitope presents a unique challenge
for the scaffolding approach as it naturally tends to adopt a helical
conformation as defined by NMR or by structures of the post-
fusogenic conformation of gp41 [43,44,45,46]. However, in
complex with the 2F5 antibody, this region assumes an extended
loop conformation [47,48]. As immunogens inoculated into guinea
pigs, the 2F5 ES proteins elicited antibodies with exquisite binding
specificity matching that of the parental 2F5 antibody [41].
The creation of the novel 2F5 epitope-scaffold (ES) proteins
suggested a strategy to focus antibody responses to the conserved
2F5 epitope by designing and inoculating in series a set of
unrelated scaffolds displaying the 2F5 determinant as the only
epitope in common. This approach also eliminates glycan
occlusion and immunodominant gp120 variable regions, which
may obscure or divert the antibody response from desired broadly
neutralizing Ab determinants in gp41 or gp120. The aim of this
approach is to prime B cell responses to the 2F5 epitope displayed
by one of the ES proteins then to boost with unrelated ES proteins
displaying the same 2F5 epitope to selectively stimulate memory B
cells specific for the shared antigenic determinant.
In the current study, using selected 2F5 ES proteins, we
demonstrated efficient heterologous prime:boosting that, with each
succeeding boost, increases elicitation of 2F5 epitope-specific
antibodies and B cells. We observed that, in the heterologous
prime:boosting regimen, incorporation of a linked T cell helper
epitope (TH) in the immunogens was advantageous to the 2F5
epitope-specific elicitation at the serum antibody binding level and
at the secretory B cell level. Most importantly, we observed
profound alterations in presentation of the 2F5 epitope graft to
elicit B cell responses that was scaffold context-dependent. As
before, we observed that only one epitope scaffold combination
(ES5) efficiently elicited 2F5 epitope-specific B cells, while two
others (ES1 and ES2), although they contained the 2F5 epitope
and fixed conformation, poorly elicited 2F5 epitope-specific
antibodies. Interestingly, following the efficient priming with
ES5, the ‘‘non-epitope-presenting’’ ES1, ES2 proteins were then
able to efficiently boost 2F5 epitope-specific B cell responses at the
polyclonal and monoclonal level. However, in no case did we elicit
2F5 epitope-directed antibody responses capable of virus neutral-
ization.
The results presented here suggest that the use of computation-
ally designed epitope scaffolds may be useful for targeting humoral
responses on structurally defined sites on viral pathogens.
Specifically, the 2F5 epitope-scaffolds provide a well-defined
system to evaluate and optimize immunization based upon this
approach, which may be required to elicit epitope-specific
responses against the well-shielded HIV-1 functional spikes.
Materials and Methods
Ethics Statement
Animal experiments were carried out at two separate locations,
the Vaccine Research Center (VRC) at the National Institutes of
Health and at the Karolinska Institutet in Sweden. All animal
experiments were approved by the Institutional Animal Care and
Use Committee (IACUC) at the NIH (approval number A4149-
01) and by the Swedish committee Stockholm’s Norra Djurfo ¨rso ¨-
ketiska Na ¨mnd (approval number N475/09), and performend
according to given guidelines.
Cloning, expression and purification of 2F5 epitope
scaffolds
Plasmids for expression of the 2F5 ES fusion proteins termed
ES5, ES1, ES2 and ES4 were initially derived by de novo gene
synthesis and subcloning into the mammalian expression vector,
CMVR as previously described [41]. The acceptor scaffolds were
based upon proteins with the Protein Data Base designation
1d3bb, 1lgya, 1ku2a and 1iwla respectively. The fusion proteins
ES2 and ES4 did express in the mammalian system. However,
scaffolds ES5 and ES1 did not express in the mammalian system
and were subcloned into a bacterial expression vector (pET-17b,
Novagen). Versions of the scaffolds ES1, ES2 and ES5 with an
engineered universal heterologous T cell helper epitope (AFK-
VAAWTLKAAA) at the C-terminus were derived by Quick-
change PCR mutagenesis (Stratagene). Mammalian expression of
the proteins ES2 and ES4 was carried out in 293F cell line that has
been adapted to serum-free medium (Invitrogen). In brief, the
293F cells were grown in 2L flasks to a density of 1.2610
6 cells per
ml and transfected with 250 mgs of plasmid DNA per liter of
medium using 293 Fectin transfection reagent (Invitrogen). Cell
culture supernatants were collected 4 days after transfection,
centrifuged at 3,5006g to remove cell debris and filtered using a
0.22 mm filter unit. Supernatants were applied to a His-Trap
nickel affinity column (Amersham). The column was washed with
100 ml phosphate buffer containing 20 mM imidazole, pH 7.4
and then eluted with Phosphate buffer containing 500 mM
imidazole. Eluates were concentrated and subjected to buffer
exchange with phosphate buffer pH 7.4 using Amicon ultra
10,000 MWCO centrifugal filter devices (Millipore). A second
round of affinity purification using a 2F5 mAb column was
performed. Buffer exchanged eluate from Nickel purification was
applied to the 2F5 antibody Affinity column, then washed with
100 ml of 500 mM NaCl in phosphate buffer, pH 7.4 and
proteins were eluted with IgG elution buffer, pH 2.8 (Pierce).
Elution buffer acidic pH was quickly neutralized with TRIS buffer,
pH 8.5. Eluates were pooled, concentrated and buffered ex-
changed to phosphate buffer, pH 7.4.
Scaffolds in the pET-17b vector were expressed in Rosetta
BL21 E. Coli bacteria. In brief, a 50 ml culture of transformed E.
coli was grown overnight at 37uC. The following day a 1 L culture
was grown from the overnight 50 ml culture to 0.6 OD and
expression of the protein was induced by using IPTG at a final
concentration of 1 mM, then the culture was grown for 6 more
hours. Bacteria were pelleted by centrifugation at 5,0006g and
protein was extracted from inclusion bodies. First, bacterial cell
pellets were lysed using Novagen Bugbuster reagent containing
lysozyme. Lysate was subjected to centrifugation at 10,0006g for
pelleting inclusion bodies. Isolation of the proteins from inclusion
bodies was carried out using denaturing conditions of 8 M urea
and 1 mM ß-mercaptoethanol. After filtering insoluble debris,
soluble denatured protein was purified by Nickel column in
denaturing conditions (8 M urea, 10 mM imidazole) and concen-
trated to a volume of 1 ml using the Amicon Ultra (Millipore).
Protein refolding was done at 4uC by quick dilution (1/100) into
an appropriate refolding buffer and incubating at 4uC for 16 hrs.
Refolding buffer contained 50 mM Tris pH 8.0, 250 mM NaCl,
500 mM L-Arginine, 0.1 mM glutathione reduced, 0.01 mM
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chloride. The refolded proteins were then concentrated to
approximately a volume of 5–7 mL using centricon plus-80
(Millipore) and dialyzed to PBS 125 mM NaCl using a dialysis
cassette (Pierce). A second round of purification using a 2F5
antibody affinity column was carried out for ES5. However, ES1
was only Nickel purified due to insolubility at acidic elution
conditions.
SPR kinetic binding analysis
All kinetic reactions were performed at RT on a Biacore 3000
surface plasmon resonance spectrometer. To prepare binding
surfaces with approximately 500 RU per cell, 10 mg/ml of ligand
2F5 antibody in 10 mM NaOAc, pH 5.5 buffer were immobilized
on a Biacore CM5 chip by the amine coupling method following
manufacturer’s protocol. The reference cell received only NaOAc
buffer. Analytes were serially diluted in the HEPES-EP reaction
buffer at concentrations ranging from 3.9 nM to 500 nM for ES5,
ES2 and ES4, and from 62.5 nM to 2000 nM for ES1. Association
was allowed for 3 min at 30 mL/min. Dissociation was determined
by washing off bound analyte over the next 3 minutes. The chip
surface was regenerated with two injections of 10 mM glycine,
pH 3.0 for 30 seconds. The kinetic rate constants were obtained by
fitting the curves to 1:1 Langmuir binding model using BIAevalua-
tion software. SPR kinetic analysis of the murine monoclonals was
done following the same format, immobilizing the IgG on a CM5
chip. The analytes ES2 and ES4 were run in the same
concentrations as used for the 2F5 antibody analysis. For this
study, we used a modified version of the gp41 MPER peptide to
enhance solubitiy and facilitate binding detection (EQELLELDK-
WASLGGGGSGGWNWFDITKWLWYIKKKKGSKKK). This
peptide was used as an analyte in a concentration series ranging
from 3.9 nM to 250 nM for both the 2F5 and the murine
monoclonal antibody SPR kinetic analysis.
ELISA
200 ng/well of antigen was incubated overnight at 4uC in wells
of a Maxisorp high binding plate (Nunc) in PBS, pH 7.4. The next
day plates were washed five times with PBS, pH 7.4 containing
0.2% Tween 20 and blocked with 300 mL per well of PBS, pH 7.4,
supplemented with 2% dry-milk powder (Difco) and 5% heat-
inactivated Fetal Bovine Serum (Sigma or Gibco) for 2 hrs at RT.
Plates were washed five times with PBS, pH 7.4, 0.2% Tween 20.
Serum was serially diluted fivefold (1:50 to 1:781,250) in PBS
pH 7.4, 0.2% Tween 20 and incubated for 1 hr at RT. Plates were
washed five times with PBS pH 7.4, 0.2% Tween 20 and a goat
secondary anti-mouse immunoglobulin G (H+L) (Jackson Labs)
was incubated at a 1:10,000 dilution in PBS pH 7.4, 0.2% Tween
20 for 1 hr at RT. Plates were washed five times with PBS pH 7.4,
0.2% Tween 20 and 100 ml of colorometric TMB (3,39,5 ,5 9-
tetramethylbenzidine) peroxidase enzyme immunoassay substrate
(Bio-Rad) was added to each well, and the reaction was stopped by
adding 100 ml of 0.1 N H2SO4 to each well. The optical density
was read on a microplate reader (Molecular Devices) at 450 nm
using Softmax software.
Animal immunizations and cell preparation
Adult female C57BL/6 mice (The Jackson Laboratory) received
three inoculations subcutaneously with 20 mg of protein formulat-
ed in 10 mg AbISCOH-100 adjuvant (Isconova AB) at two weeks
intervals. Pre-bleeds prior to first inoculation as well as bleeds were
collected 7–10 days after each inoculation. Serum was incubated
at 55uC for 1 hr to heat-inactivate complement and stored at
280uC until subjected to analysis. Three or four days after
inoculation, single cell suspensions were prepared from spleen and
lymph node (LN) by passing the tissue through a nylon mesh. Red
blood cells were lysed with hypotonic ammonium chloride
solution. After washing, the cells were resuspended in complete
RPMI medium containing 5% FCS, 50 mM b-mercaptoethanol,
2 mM L-glutamine, 100 U/ml penicillin and 100 mM streptomy-
cin (all from Sigma). Cells were then added to ELISpot plates
immediately or stimulated in vitro at a concentration of 1610
6
cells/ml in complete RPMI medium containing 2 mg/ml LPS
(Sigma) and 0.5 mg/ml CpG ODN 1826 (TriLink BioTechnolo-
gies) for 6 days. The in vitro stimulation allows for memory B cell
expansion and differentiation into antibody-secreting plasma cells
that can then be detected in the ELISpot assay.
B cell ELISpot assays
The procedure and optimization of the B cell ELISpot assay was
described in detail elsewhere [49]. Briefly, 96-well MultiScreen-IP
filter plates (Millipore) were pre-treated with 70% ethanol and
washed 3 times in sterile PBS, before coated with 1 mg/well of a
polyclonal goat anti-mouse IgG antibody (Mabtech AB). The
plates were incubated overnight at 4uC. Before addition of the
cells, plates were washed 5 times in sterile PBS and then blocked
with complete RPMI medium at 37uC for 2 hrs. Cells were added
in duplicates to the wells in 3-fold serial dilutions, starting at 2,000
cells/well for hybridoma cells, 1610
6 cells/well for splenocytes
and 1.3610
6 originally cultured cells/well for the in vitro stimulated
cells. Plates were wrapped in plastic and incubated for 12 hrs at
37uC. For detection of spots, the cells were removed by washing
the plates 6 times in PBS containing 0.05% Tween 20. For
detection of total IgG secreting cells, 0.1 mg/well of a biotinylated
polyclonal goat anti-mouse IgG (Mabtech AB) was added in
blocking buffer (PBS containing 1% FCS and 0.05% Tween 20).
For detection of graft-specific B cells, biotinylated 2F5 peptide
(EQELLELDKWASLW) (0.1 mg/well) or control protein b-
galactosidase (0.2 mg/well) were added as probes diluted in
blocking buffer. Biotinylated probes were incubated in the plates
for 2 hrs at room temperature (RT). Responses to protein epitope
scaffold used as immunogens were measured with unbiotinylated
probes. In this case, an additional incubation step with a rabbit
anti-his tag antibody (0.2 mg/well) (Immunology Consultants
Laboratory, Newberg OR) was performed. Plates were then
subjected to 6 washes of PBS containing 0.05% Tween 20 before
addition of 100 ml of alkaline phosphatase (ALP)-conjugated
streptavidin (Mabtech AB) diluted 1:1000 in PBS. Plates were
incubated for 45 min at RT and then washed 6 times in water.
100 ml of BCIP/NBT-plus substrate (Mabtech AB) was added and
incubated for 10 min at RT. Plates were then washed extensively
with water and air-dried. Spots were counted in an ImmunoSpot
R
analyzer (Cellular Technology Ltd.).
Epitope-scaffold elicited mouse monoclonal antibodies
As previously described [41], Balb/c mice were inoculated
subcutaneously with 20 mg of protein in Alum and CpG
combination adjuvant following either a homologous regimen of 5
inoculations of ES5 or a heterologous prime:boost regimen of two
inoculations of ES5 followed by 3 inoculations of ES1. For this
study, we included analysis of monoclonals derived in parallel from
mice inoculated 5 times with the ES1 immunogen and isolated and
characterized as previously described [41]. In brief, ELISA IgG
titers measured using heterologous ES2 protein or (EQELLELDK-
WASLWNWFDITKWLWYIKKKKGSKKK) gp41 MPER pep-
tide were used to determine mice that were to be sacrificed to
proceed with fusion of splenocytes to generate hybridoma cells. 2F5
epitope-specific clones were selected on ES2, ES3 and ES4 epitope-
Heterologous 2F5 Epitope-Scaffold Prime:Boosting
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ES1-derived monoclonals (14B, 14E and 5C1) and the previously
described monoclonals (1D9, 1C1, 9F8 and 11F, 6A7, 6F4).
Results
Biophysical characterization of the 2F5 epitope-scaffolds
(ES)
For the serial prime:boost immunogenicity analysis that was the
focus of this study, we characterized a subset of the previously
described epitope-scaffolds, namely ES1, ES2, ES4 and ES5 (see
Fig 1 for schematic fusion protein models and graft sequences).
Because several of the ES are relatively short in linear sequence,
and might be deficient in T cell helper epitopes, all of the
immunogen proteins were designed either lacking or possessing a
promiscuous, heterologous T cell helper epitope at the C-terminus
(previously called TH, similar to PADRE, [50]).
Following expression and purification, the ES1, ES2 and ES5
immunogens, either lacking or possessing the promiscuous TH,
were determined to be relatively homogenous by SDS PAGE
(Fig 2A). In each case, the TH-containing epitope scaffolds
migrated more slowly in the gel, consistent with the presence of the
13 residue, TH, C-terminal adduct. Binding recognition of the ES
proteins by the 2F5 monoclonal antibody was determined both by
Surface Plasmon Resonance (SPR) (Fig 2B) and by ELISA (data
not shown). The affinity of 2F5 for each of the ES proteins was
determined by immobilizing the 2F5 antibody to the surface of the
SPR chip and flowing the ES proteins as solution analytes over the
surface. In this configuration, the affinity of 2F5 for the ES2, ES5,
ES1 and ES4 analytes was determined to be 1.1, 41.1, 71.1 nM
and 85.2 nM, respectively. Some of these values differ slightly
from our previous report, in which case the ES proteins were
attached directly to the solid phase SPR chip, and the 2F5
antibody Fab was configured as the analyte [41]. These are
relevant affinity differences to report as they might be relevant to
the differential presentation of the 2F5 epitope to the immune
system in selected scaffold contexts. It is likely that the observed
‘‘apparent affinity differences’’ between the two configurations
may be indicative of some oligomers of the ES proteins in solution,
resulting in a partial occlusion of the 2F5 graft as well as avidity
gain that could influence the observed apparent affinity. In any
case, this alternative and new SPR analysis revealed that the
ES5 protein, showed considerably slower dissociation rates
(4.13610
24 s
21) as compared to the rates of other ES proteins,
which were 5 to 10 times faster in their off-rates (Fig 2B). The
slower observed dissociation rate may be a result of oligomeriza-
tion of the ES5 protein in solution and may contribute to its ability
to enhance anti-2F5 epitope responses in our present (and past)
immunogenicity study. By this analysis, the 100-fold more rapid
on-rate of 2F5 to the ES2 protein was consistent with our previous
observation that the 2F5 epitope may be more tightly locked into
the extended loop conformation [41]. Presumably, this conforma-
tional constraint was accomplished by underlying protein-protein
interactions, as modeled during the design of this epitope-scaffold
combination.
Immunogenicity of ES in a homologous regimen
We first analyzed the responses in animals inoculated
subcutaneously with 20 mg of the proteins ES1, ES2 and ES5 in
Abisco-100 adjuvant using a homologous immunization regimen
of three immunizations, two weeks apart. We determined that in
the three homologous regimens performed in parallel, all three ES
proteins were relatively immunogenic in the C57BL/6 mice,
consistent with our recent experiments performed in outbred
guinea pigs [41].The elicited antibody binding titers to each ES
protein saturated after three inoculations, with relatively high
Figure 1. The 2F5 epitope scaffold (ES) fusion proteins. (A) Left, in red the 2F5 gp41 epitope region is shown both in the post-fusogenic
helical form (PDB 3K9A) and in the 2F5-bound conformation (PDB 1TJI). The gp41 membrane proximal external region (MPER) including the 2F5
epitope adopts most frequently an alpha-helical conformation, however, it forms an extended ß-turn loop conformation when bound to the 2F5
antibody, as described in [48]. Structural models (pymol) of the ES proteins used as immunogens ES5 (blue), ES1 (green) and ES2 (red), respectively.
Their molecular surfaces are rendered translucent to display the underlying secondary structure. Superimposed (in red) is the 2F5 antibody-bound
peptide conformation. The conserved 2F5 epitope graft molecular surface is shown in yellow. (B) Partial structure of the 2F5 antibody Fab (gray)
docked to the model of ES4 (orange). ES4 was used as an antigenic probe to measure epitope-specific responses to the conformationally constrained
2F5 epitope and was not used as an immunogen. (C) Alignment of the gp41 2F5 epitope and the ES graft sequences; the 2F5 antibody contact
residues defined in the 2F5 antibody-peptide structure are emboldened and underlined.
doi:10.1371/journal.pone.0016074.g001
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ES1 and ES2) (Fig 3A). These ES-recognizing serum antibody
responses are directed to the entire surface of each respective
inoculated ES (blue, red and green surfaces for each ES
respectively, along with the yellow 2F5 epitope graft; see Fig 1A).
As seen in Fig 3A, the presence of the heterologous TH was not
required for any of the ES proteins to be immunogenic when
inoculated in a homologous regimen.
Next we sought to assess the capacity of the ES immunogens to
elicit antibody responses specific for the 2F5 epitope using two
different 2F5 epitope targets. Note that, here, we are measuring only
the serum antibody response directed exclusively to the 2F5 epitope
graft (yellow surface on the pymol models in Fig 1A). First, we
measured binding to the free 2F5 peptide captured on the ELISA
plate (Fig 3B). Second, and in parallel we measured binding to the
ES4 proteintarget captured on the plate (Fig S1). Recallthat ES4was
not inoculated into the mice and displays the bound conformation of
the 2F5 epitope, and has no sero-cross reactivity with any of the other
acceptor scaffolds. Therefore, the ES4 target is recognized only by
graft-specific antibodies specific for the 2F5-bound conformation of
the epitope. Using these two probes, we observed that, after three
inoculations, ES5 elicited near saturating levels of 2F5 epitope-
specific responses with endpoint titers of 1:156,250 to the 2F5 epitope
peptide and ES4 (Fig 3B and Fig S1). Furthermore, the binding of the
ES5-elicited serum antibodies to both peptide and ES4 was
confirmed to be specific using a 2F5 antibody cross-competition
Figure 2. Biophysical characterization of the ES proteins. (A) SDS-PAGE gel of ES proteins used as immunogens after affinity purification. The
ES proteins possessing the C-terminal heterologous T cell helper residues are denoted ‘‘+TH’’. (B) The recognition of the ES proteins by the 2F5
monoclonal antibody was assessed by surface plasmon resonance (SPR) in a Biacore 3000 instrument. In red, the observed data obtained by flowing
the ES proteins as analytes over a CM5 chip to which the 2F5 IgG antibody was immobilized. In black, fit curves when a 1:1 Langmuir model is applied
to the observed data. Affinity constant values are indicated above the curves and the rate constants are denoted below the curves.
doi:10.1371/journal.pone.0016074.g002
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required three inoculations to elicit very low, but detectable responses
directed toward the 2F5 epitope and displayed low endpoint titers of
1,250. A third pattern of responses was observed in the ES2 context,
as the 2F5 epitope graft was virtually non-immunogenic in this
context (Fig 3B). This extremely inefficient elicitation of B cell
responses to the ES2-presented 2F5 epitope may be related to its
apparent greater degree of conformational fixation as deduced from
isothermal titration calorimetric analysis of the interaction between
ES2 and the 2F5 antibody [41].
The presence of the heterologous TH did not greatly enhance
the ability of the ES immunogens to elicit 2F5 epitope-specific
responses in a homologous regimen. In fact, TH in the context of
homologous ES5 prime-boosting had a slight inhibitory effect on
antibodies elicited to the 2F5 epitope, perhaps by competing for
class II presentation in some not yet defined manner.
Figure 3. ELISA binding results of ES-elicited sera following a homologous inoculation regimen. (A) Anti-ES titers in serum of inoculated
mice (5 mice per group); upper panels depict titers obtained after immunizations with constructs not possessing the T cell helper epitope TH, and are
denoted as ‘‘2TH’’; bottom panels corresponds to immunizations of constructs possessing the T cell helper epitope and are denoted as ‘‘+TH’’. (B) ES-
elicited serum binding titers measured against the 2F5 peptide adsorbed to the ELISA plate. (C) Competition between ES5-elicited serum (at a 1:2000
dilution) and the 2F5 mAb (serial concentrations) for binding to peptide (left) and ES4 (right) absorbed to the ELISA plate. Open circles represent
binding of ES5 sera in the absence of the 2F5 mAb competitor and closed circles represent binding of the ES5 sera in the presence of increasing
amounts of the competitor 2F5 mAb.
doi:10.1371/journal.pone.0016074.g003
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monoclonal antibody level
We sought to determine if heterologous prime:boosting could
focus the B cell response toward the commonly shared 2F5
epitope, especially on scaffolds that do not efficiently present the
2F5 epitope to the humoral immune system on their own. This
could be advantageous for scaffolding or other structure-guided
immunogen approaches where, perhaps, a less fixed conformation
could first prime a B cell response, and then, a more
conformationally fixed, and superior structural mimetic, might
drive the desired subset of memory B cells to a desired epitope. As
in the classic hapten-carrier immunogenicity experiments [51,52],
the goal was to induce anti-hapten antibody titers with disregard to
the protein carrier, here we aimed at eliciting anti-gp41 2F5
epitope responses, disregarding the responses to the protein
scaffold that carries the epitope-graft on its surface. In principle,
this might better elicit antibodies against a more highly
constrained, but less immunogenic, neutralizing determinant.
We selected the order of ES5 to ES1 to ES2 based upon the
relative immunogenicity of the graft as observed in both guinea
pigs and mice and evaluated ES both lacking and containing
linked heterologous T cell help. In this regimen (Fig 4A), each ES
was inoculated once to easily determine the origin of the antibody
response. The results in Fig 4B demonstrated that heterologous
prime:boosting amplified the response to the 2F5 epitope graft, as
shown using both the 2F5 epitope peptide and the non-inoculated
ES4 protein as coated target antigens in the ELISA. Quite
interestingly, the ES2 epitope-scaffold, which elicited virtually
undetectable antibodies to the 2F5 epitope as either a prime or a
boost in the homologous setting, efficiently boosted responses
specific for the 2F5 epitope once primed by the highly
immunogenic ES5 protein (Fig 4B). ES5 also primed for a
substantial increase in 2F5 epitope antibodies when boosted by
ES1. The presence of the TH sequence enhanced the graft-specific
responses in the heterologous prime:boost setting of ES5 prime,
followed by ES1 boost 1, followed by ES2 boost 2. In this instance,
the 2F5 epitope-specific endpoint titers reached 1:31,250 similar to
the levels achieved by homologous ES5+TH inoculation, but
lower than the levels elicited by ES5 lacking heterologous help
(compare Fig 4B right panel to Fig 3B lower panel to Fig 3B upper
panel). In contrast, less efficient heterologous prime:boosting of
responses using the isogenic constructs lacking linked T cell help
was observed, with 2F5 epitope-specific endpoint titers decreased
to 1:6,250 (Fig 4B).
These serological responses described above indicated that the
2F5 epitope-specific antibody responses were elicited from
established 2F5 epitope-specific memory B cells in the heterolo-
gous ES regimen, as titers to the 2F5 epitope were increased after
the ES1 and ES2 boosts. Furthermore, at the conclusion of the
regimen, total 2F5 epitope-specific titers were substantially higher
in the heterologous regimen than those elicited by a single ES5
inoculation examined over the same time interval, confirming that
the 2F5 epitope-specific titers were not simply a result of priming
with the immunogenic ES5 epitope-scaffold, followed by time-
dependent increases in titer (Fig 4C). Taken together, these data
suggest that boosting of 2F5 epitope-specific memory B cells
occurred in the heterologous prime:boost regimen. Despite the
efficient boosting of 2F5 epitope-specific responses, neither the
homologous nor the heterologous regimens resulted in the
elicitation of neutralizing antibodies that could be confirmed to
be MPER-specific by the previously described 2F5 epitope-peptide
inhibition of neutralization [53].
To assess if an advantage of heterologous prime:boosting could
be seen by an alternative means of analysis, monoclonal antibodies
(Mabs) were generated from mice immunized by either a
homologous regimen, comprised of 5 inoculations of ES5 or ES1,
or a heterologous regimen consisting of 2 inoculations of ES5,
followed by 3 inoculations of ES1. Recall that because of its poor
presentationofthe2F5epitope,5 inoculationsof ES1wererequired
to elicit an anti-2F5 epitope response of enough magnitude to
proceed with isolation of ES1-elicited Mabs. As previously reported,
the Mabs displayed similar binding specificity as the parental,
human 2F5 antibody. Structural studies of two of the Mabs (11F
and 6A7) showed that they induced the same ß-turn extended loop
conformation when bound to the 2F5 peptide as the 2F5 antibody
itself [41]. In the heterologous regimen, consisting of ES5 followed
by ES1 inoculation, three booster inoculations of ES1 generated a
2F5 epitope-specific response that allowed the isolation of Mabs. As
determined by SPR analysis (Table 1 and [41]), the Mabs derived
from the heterologous regimen (ES5 primed, ES1 boosted) mice
demonstrated higher affinity to the conformational probes (ES4 and
ES2) than the Mabs generated from the homologous regimens of
ES5 alone or ES1 alone. The affinity of ES1-elicited Mabs values
was closer to the MAbs elicited by heterologous ES5+ES1
immunization, which is consistent with the generation of an ES1-
biasedmemoryresponsewhen theES5-primed memoryresponseto
the 2F5 graft is driven by ES1 boosting.
Analysis of responses to the 2F5 epitope graft at the B
cell level
To determine the frequency of 2F5 epitope-specific B cells
stimulated by the homologous and heterologous prime:boosting
regimens, we established a 2F5 epitope-specific B cell ELISpot
assay. By capturing all IgG-secreting cells and detecting antigen-
specific spots with biotinylated probes an increase in resolution
and less non-specific background was observed [49]. To first
confirm the specificity of the 2F5 epitope-directed B cell ELISpot
assay, we utilized a 2F5-like murine monoclonal antibody cell line
1D9. This hybridoma was generated by standard hybridoma
fusion from mice inoculated with a regimen using the ES5 protein
in adjuvant [41]. The hybridoma was selected by screening their
secreted antibodies by binding to heterologous ES proteins (i.e.,
ES2, ES4), thus only selecting cells with 2F5 epitope-graft
specificity. In brief, hybridoma cells were plated at selected
densities to ELISpot plates coated with an anti-mouse-IgG
polyclonal rabbit IgG and specific antibody was detected using
biotinylated 2F5 epitope peptide followed by strep-avidin-HRP
(Fig 5A). Hybridoma cells were plated at three different
concentrations and a titration of the biotinylated 2F5 peptide
was carried out to optimize the signal. An irrelevant peptide of
similar length was used at highest concentration (0.5 ug/mL) as a
negative control (Fig 5B). Recognition was achieved by the
biotinylated 2F5 epitope peptide probe of secreted IgG ‘‘spots’’
from the 1D9 2F5-epitope-specific hybridoma cells for essentially
all antibody secreting cells, validating probe specificity (Fig 5C).
Having confirmed detection of 2F5 epitope-specific responses
by the B cell ELISpot assay, we inoculated 15 mice per group
(sacrificing 5 mice at each time point to collect B cells) with the
epitope-scaffolds in adjuvant to assess B cell responses elicited by
regimens analogous to those analyzed at the level of circulating
antibodies. Epitope-scaffolds were inoculated either in a homol-
ogous manner for each fusion protein (i.e., ES5 prime, followed by
two ES5 boosts) or in a heterologous sequential manner (ES5,
followed by ES1 and ES2 sequential boosts). To ensure that
immunogen-linked T cell help was functional, we inoculated ES
containing the C-terminal heterologous TH sequences into
C57BL/6 mice containing the I-A
b class II molecules, which the
TH epitope binds with high affinity. 2F5 epitope-specific B cell
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detected after 3 inoculations in the ES5 homologous and the
heterologous prime:boosting groups with mean values of 1.75%
and 1.22% antibody-secreting cells (ASC) of total IgG secreting
cells, respectively (Fig 6A). These values were significantly higher
than negative control responses to control protein ß-gal and
significantly higher than those obtained after a single ES5
inoculation control animals (Fig 6B). The percentages of 2F5
epitope-specific ASC stimulated by ES5 homologous compared to
the heterologous prime:boost are of the same magnitude (not
statistically significant) suggesting that the magnitude of the 2F5
epitope specific ASC response in the heterologous regimen is
originating from effective ES1 and ES2 boosts that followed the
ES5 prime inoculation. Notably, neither ES1 nor ES2 elicited 2F5
epitope-specific B cell responses in the homologous format after 1,
2 or 3 inoculations (Fig 6A).
Figure 4. Heterologous prime:boost regimen ELISA titers. (A) Schematic representation of the heterologous prime:boosting regimen. (B) 2F5
peptide (top) and not inoculated ES4 (bottom) binding serum titers of pooled sera from 5 mice following a heterologous prime:boost immunization
regimen (ES5-ES1-ES2) with or without T cell helper epitope (+/2TH). (C) To confirm that the epitope specific responses obtained in the heterologous
regimen were not a result of the first (priming) inoculation with the immunogenic ES5 protein, which then increase over the time of the experiment,
we inoculated 5 mice once with ES5 and measured sera binding titers after the same time interval of the complete heterologous prime-boosting
regimen (34 days).
doi:10.1371/journal.pone.0016074.g004
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the spleen, we performed the B cell ELISpot assay on splenocytes
collected 3 days after the third immunization and cultured in vitro
in the presence or absence of LPS (i.e., stimulated or unstimulated,
Fig 6C). Following 6 days in vitro incubation with LPS to allow for
proliferation and differentiation of antigen-experienced memory B
cells into plasma cells, we observed a greater number of 2F5
epitope-specific spots, indicating that epitope-specific memory B
cells were generated. The heterologous prime:boost group showed
a greater expansion than a single ES5 inoculation, suggesting that
the recall response in the heterologous regimen is the result of an
amplification of the 2F5 epitope-specific response obtained with an
effective prime:boost and not just the result of the ES5 initial
priming inoculation. For the heterologous group, in cells not
stimulated with LPS, less than 5 2F5 epitope-specific B cells per
million cells plated were detected whereas, with LPS stimulation,
approximately 15 cells per million cells plated were detected
(Fig 6C, left panel). In ß-gal inoculated control mice, the antigen-
specific B cell levels increased from approximately 198 in the
absence of LPS to 911 in the presence of LPS (Fig 6C, right panel).
The greater frequency of memory B cells specific for ß-gal likely
reflects that this is a large protein, not just a single epitope as in the
case of the engrafted 2F5 epitope. Consistent with this interpre-
tation, we observed considerably more spots when we quantified B
cells directed against the complete ES proteins compared to
against the 2F5 epitope alone (Fig 6B and not shown).
Discussion
In this study we investigated the potential advantage of using
heterologous prime:boosting to focus the B cell response on a
structurally defined, conformational, continuous neutralizing HIV-1
Env determinant known as the 2F5 epitope. We demonstrate that,
consistent with our earlier studies on this subset of scaffolds, only the
ES5 protein efficiently presents the 2F5 epitope ‘‘graft’’ in an
immunogenic manner at both the serum antibody and B cell level. In
contrast, although the ES1 and ES2 constructs themselves are
immunogenic overall, they do not efficiently present the 2F5 epitope
graft to the B cell compartment of the immune system. Additional
linked T cell help does not overcome the poor 2F5 epitope
immunogenicity in the homologous prime:boost regimen involving
either ES1 or ES2. These results indicate that the poor immunoge-
nicity of the 2F5 epitope in context of these immunogens is not due to
poor elicitation of T cell helper responses by these proteins. In
contrast, the linked T cell help does increase the efficiency of
heterologous prime:boosting of the 2F5 epitope by ES1 and ES2, as
long as ES5 first primes the 2F5 epitope-specific antibody/B cell
responses. These data demonstrate that the non-immunogenic, ES2
(in terms of eliciting 2F5 epitope-specific responses), is capable of
effectively driving 2F5 epitope-specific memory B cell responses if
effectively primed. However, the magnitude of the 2F5 epitope-
specific responses are not higher when elicited by the heterologous
regimen compared to levels elicited by three homologous ES5+TH
inoculations at either the serum antibody level or the B cell level, and
were in fact lower than binding elicited by homologous ES5
prime:boost lacking TH. Taken together, the data indicate that to
achieve efficient heterologous prime:boosting, it appears important, if
not critical, to prime the response with an ES that efficiently presents
the 2F5 epitope target to the immune system and to include linked T
cell help in each immunogen.
There are some hints that the quality of the response subtly
changes with heterologous prime:boosting compared to the
homologous ES5 immunization, suggesting that the heterologous
scaffolding approach, when optimized, might be capable of
influencing the specificities of a given B cell response. That there
were slight improvements observed in the binding properties of the
Mabs elicited by heterologous ES5 to ES1 prime:boosting
compared to ES5 homologous prime:boosting, suggests that
prime:boosting may have some advantages if improvements in
the immunogen design can be implemented. However, neutral-
ization of HIV-1 was not elicited by any of the regimens tested in
the study nor by any of the ES-elicited Mabs. Perhaps this is an
issue of elicited antibody affinities for the bona fide, but as yet
structurally undefined, 2F5 epitope in the native Env context. Or
perhaps this is due to the lack of a lipid bilayer context in the
immunogen. Eliciting antibodies similar to the parental 2F5 might
require more hydrophobic surfaces to be present in the ES to drive
the elicitation of antibodies capable of cross-reacting with the
functional HIV-1 spike.
Why the ES5 protein presents the 2F5 epitope graft in a much
more immunogenic manner in contrast to the other ES proteins
testedhereis unclear. In ourpreviousstudywe showed a correlation
between epitope flexibility and the ES capacity to generate epitope
specific antibodies. Likely there are multiple factors involved that




Ligand Mabs: 2F5 1D9 9F8 1C1 14B 14E 5C1 6A7 11F 6F4
Analyte Peptide* KD (nM) 3.6 35.8 80.5 241 49.3 43 44.9 29 28 29
Kon (1/Ms) 10
4 71.1 120 87.9 13.6 95.2 114 96.3 197 129 117
Koff (1/s) 10
23 2.5 42.8 70.8 32.9 47 48.9 43.2 57 37 34
ES2 KD (nM) 2.6 563 2070 2020 94.5 74.9 82.5 87 71 71
Kon (1/Ms) 10
4 95 9 1.9 0.4 105 103 87.4 134 102 99
Koff (1/s) 10
23 2.5 51 39.3 8.6 99.7 77.3 72.1 117 73 71
ES4 KD (nM) 85.2 2460 2380 - 362 360 341 1040 215 213
Kon (1/Ms) 10
4 3.51 8.7 8.9 - 3.9 3.4 4 4.28 7.58 7.53
Koff (1/s) 10
23 2.99 216 212 - 14.2 12.3 13.7 44 16 16
*peptide sequence EQELLELDKWASLGGGGSGGWNWFDITKWLWYIKKKKGSKKK.
-indicates no detectable binding.
doi:10.1371/journal.pone.0016074.t001
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immune system. Is it that ES5 is a small scaffold with less (other)
competing surface B cell epitopes or, similarly, that ES5 lacks
competing immunodominant flexible loop epitopes? Or is it,
perhaps, the oligomerization and occlusion of irrelevant scaffold
epitopes? Studies to answer some of these questions are ongoing,
such as ‘‘loosening’’ the graft in the ES2 context to determine the
resulting biophysics and immunogenicity. This well-defined system
highlights the different challenges between rendering a linear
determinant (here) immunogenic, compared to applying this
approach to a more complex conformational determinant such as
the CD4 binding site of gp120 (recognized by the broadly
neutralizing antibodies b12 and VRC01).
It seems unlikely, as has been suggested [54], that potential B
cells recognizing the 2F5 epitope are deleted due to mimicry of
some self epitope since, in the ES5 homologous immunization
regimen and in the heterologous ES5-ES1-ES2 regimen there are
substantial responses to the epitope. However, these ES were
designed without regard to the undefined hydrophobic epitope
contacts that presumably are made by the third complementarity-
determining region of the heavy chain (CDRH3) of the antibody
2F5, which might be responsible for the self-specificity attributed
to the antibody. Definition of these contacts of the 2F5 antibody
might be necessary to further improve on the design of ES
combinations capable of eliciting 2F5-like neutralizing antibodies.
In a recently published study, a similar scaffolding approach was
utilized to present the poorly immunogenic gp41 4E10 epitope,
which is located adjacent to the 2F5 epitope in the viral Env [42].
While the 4E10 ES elicited antibodies with an antigenic profile
similar to the parental 4E10 monoclonal antibody, these 4E10
epitope-specific titers were quite low. The data presented here
suggests that one way to potentially overcome the weak responses
to the 4E10 epitope would be to adopt a heterologous prime:boost
strategy, perhaps by selecting the most immunogenic 4E10 ES as a
prime and then boost with other 4E10 ES proteins that best mimic
the epitope-bound conformation. In this scenario, as shown here,
it would likely be important to include linked T cell help in the ES
immunogens as was demonstrated in the current study for
heterolgous ES prime:boosting.
In a separate recent study, we demonstrated that the on-rate of
ligands to the conformational gp120 co-receptor binding site is
increased by conformational stabilization, resulting in an increase
of antibodies targeted to the stabilized site [55]. These data
suggested that perhaps conformational stabilization of a specific
determinant might consistently enhance immunogenicity. In
contrast, here, conformational fixation of the linear 2F5 epitope
(by scaffolding) appears to decrease immunogenicity, at least in the
ES2 context. Why this is so is not entirely clear. In part, there may
be distinct B cell repertoire differences for the HIV-1 gp120 co-
receptor binding site compared to the MPER. For the two sites,
the virus may evade neutralization by one means completely
different from the other, in part due to virus/Env fitness
constraints. For the co-receptor site, HIV-1 evades the neutrali-
zation capacity of this antibody response by employing two
receptors so that the CCR5 co-receptor site it is not exposed until
after engagement of CD4 on the target cell. Therefore, it can
tolerate avid responses to the occluded CCR5 binding site without
a large cost to viral viability. However, to dampen responses to the
presumably functionally conserved MPER, perhaps other means
of immune evasion have been selected for in the host. The need by
the virus to limit neutralizing antibodies to hydrophobic MPER
was suggested previously to occur by some form of virus mimicry
to ‘self’ human antigens [54].
Figure 5. Validation of the B ELISpot using the biotinylated 2F5
peptide as a probe to measure epitope specific antigen
secreting cells (ASC). (A) Schematic depiction of the modified B cell
ELISpot assay [49] where all secreted antibodies are captured by rabbit
anti-mouse IgG, then a biotinylated anti-mouse IgG probe is used to
determine total IgG responses or a biotinylated 2F5 peptide probe is
used to determine the 2F5 peptide-specific ASC. (B) ELISpot plate
showing immuno spots generated by the hybridoma cells expressing
the murine monoclonal antibody 1D9 [41] which binds the 2F5 epitope.
(C) As shown by the 1:1 correspondence, the 2F5 peptide probe binds
nearly 100% of the hybridoma secreted antibodies.
doi:10.1371/journal.pone.0016074.g005
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were generated by means of a heterologous ES prime:boosting
immunization regimen. This effective prime:boost response re-
quired priming with an immunogenic (to the epitope target) ES as
well as linked T cell help via addition of the T cell helper epitope
adduct in all ES immunogens. Non-immunogenic ES, but perhaps
more loyal mimics of the targeted epitope can serve as boost
proteins as long as priming is achieved with another ES. There is a
need to make this process more efficient and capable of generating
anHIV-1neutralizingantibodyresponse.Inpart,thismightrequire
the optimization of conformational fixation, while at the same time
maintaining immunogenicity of the linear 2F5 epitope determinant.
Supporting Information
Figure S1 Epitope graft-specific titers. Anti-ES4 titers
(ES4 not utilized as immunogen) elicited with ES homologous
immunization regimens. Panels on the top depict antibody
responses of sera pooled from 5 mice prior to the first inoculation
and after 1, 2 and 3 inoculations of ES protein immunogens
lacking the heterologous T cell helper epitope (TH), and the
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